Sunday 18 October 2026 Export XAIR’s income statement to Excel — free account

Beyond Air, Inc.

Beyond Air, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $7.7 million, up 107.3% from fiscal 2025. In the quarter to June 2026, revenue was flat, EPS grew 64.1%, free cash flow fell 9.10% and total debt rose 127.3%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

2.16 0.05 −2.26%

Follow XAIR

Alert me

Market cap: $2.2M
P/E: 0.0×
Fwd P/E: −0.3×
Dividend yield: —
F-score: 5/9
Altman Z: −14.40
Beneish M: −11.92
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.29

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	2	—	1	1
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 2.18

Revenue 7.69

Net Income (34.41)

Free Cash Flow (19.60)

Net Debt 7.18

Current Ratio 3.31

Debt/Equity 7.89

P/E ratio 0.00

Fwd P/E (0.27)

P/S ratio 0.20

P/B ratio 0.55

Past 5Y EPS Growth —

This Y EPS Growth 53.12%

Next Y EPS Growth 33.51%

Next Y revenue growth 117.74%

Next 5Y EPS Growth 45.76%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.12%

10-year low 10-year high

P/B against its own 10 years 1.96%

10-year low 10-year high

EV/Sales against its own 10 years 3.31%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	35	7	17	15
Receivables	0	1	1	1
Inventory	2	2	1	1
Other	7	6	5	5
	44	16	25	23

	2024	2025	2026	Q'26
Payables	2	2	2	2
ST’ Debt	1	1	0	0
Other	—	—	—	—
	12	5	7	7

Compound Annual Growth %

	10y	5y	3y
Sales	—	(0.12%)	106.43%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(27.25%)	(47.13%)

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	2	—	—	—	—
’26	2	2	2	2	8
’25	1	1	1	1	4
’24	0	0	0	0	1
’21	0	0	0	0	1
’20	1	1	0	0	1

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(5)	—	—	—	—
’26	(5)	(4)	(4)	(5)	(18)
’25	(10)	(13)	(8)	(7)	(38)
’24	(17)	(14)	(14)	(11)	(56)
’23	(7)	(9)	(9)	(8)	(33)
’22	(4)	(5)	(6)	(8)	(23)
’21	(5)	(3)	(5)	(6)	(20)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(5)	—	—	—	—
’26	(5)	(5)	(4)	(5)	(19)
’25	(13)	(15)	(8)	(8)	(44)
’24	(18)	(16)	(15)	(13)	(62)
’23	(7)	(10)	(9)	(10)	(37)
’22	(4)	(6)	(7)	(8)	(25)
’21	(6)	(4)	(5)	(6)	(21)

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	(11.00)	—	—	—	—
’26	(30.60)	(25.00)	(17.00)	(15.40)	(80.20)
’25	(108.00)	(112.00)	(60.00)	(36.00)	(276.00)
’24	(180.00)	(204.00)	(200.00)	(144.00)	(728.00)
’23	(148.00)	(160.00)	(172.00)	(268.00)	(744.00)
’22	(124.00)	(144.00)	(116.00)	(292.00)	(672.00)
’21	(160.00)	(120.00)	(132.00)	(96.00)	(508.00)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	70.20	41.00	1,380.00	1,488.00	1,848.00	1,914.00	468.00	118.40	13.46	2.05	Analyst estimates 2027–2029 Powerpack
	High	600.00	2,196.00	2,499.60	5,000.00	6,564.00	4,704.00	3,096.00	868.00	208.00	53.20
People
People	Employees	12	—	18	23	45	70	98	107	61	54
	Revenue/emp, $m	0.00	—	0.43	0.06	0.02	0.00	0.00	0.01	0.06	0.14
Income, $m
Income, $m	Revenue	—	—	8	1	1	—	—	1	4	8
	Gross margin, %	0.00	—	100.00	100.00	100.00	0.00	0.00	(112.77)	(44.89)	3.28
	EBT	(18)	—	(7)	(20)	(23)	(44)	(59)	(64)	(48)	(34)
	EBT margin, %	0.00	—	(85.30)	(1,445.71)	(2,620.27)	0.00	0.00	(5,547.45)	(1,308.48)	(447.12)
	Net income	(18)	—	(7)	(20)	(23)	(44)	(59)	(64)	(48)	(34)
	Depreciation	0	—	0	0	0	1	1	3	4	4
Per share, $
Per share, $	Revenue	0.00	—	364.34	48.27	19.40	0.00	0.00	13.98	21.88	18.50
	Earnings	(1,202.53)	—	(308.67)	(712.00)	(508.00)	(672.00)	(744.00)	(728.00)	(276.00)	(80.20)
	Cash flow	(474.60)	—	63.26	(529.52)	(436.42)	(360.34)	(440.71)	(675.68)	(225.74)	(43.71)
	Capex	(16.27)	—	(2.67)	(1.51)	(19.78)	(21.50)	(51.76)	(69.30)	(34.75)	(2.47)
	Free cash flow	(490.87)	—	60.59	(531.03)	(456.20)	(381.84)	(492.47)	(744.98)	(260.49)	(46.18)
	Book value	(558.60)	—	189.85	628.21	676.98	1,218.21	561.12	327.94	84.71	14.96
	Shares, m	0	—	0	0	0	0	0	0	0	0
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	—	—	0.00	0.00	0.00
	P/S	—	—	0.00	84.71	113.40	—	—	45.21	4.99	0.75
	P/B	—	—	10.04	6.51	3.25	—	—	1.93	1.29	0.92
	EV/Sales	—	—	0.00	69.75	78.76	—	—	28.66	5.71	1.37
	EV/FCF	—	—	28.60	(6.34)	(3.35)	—	—	(0.54)	(0.48)	(0.55)
Cash, $m
Cash, $m	Operating cash flow	(7)	—	1	(15)	(20)	(23)	(33)	(56)	(38)	(18)
	Capex	0	—	0	0	(1)	(1)	(4)	(6)	(6)	(1)
	Free cash flow	(7)	—	1	(15)	(21)	(25)	(37)	(62)	(44)	(19)
Balance, $m
Balance, $m	Working capital	1	—	3	22	33	82	40	32	11	18
	Total debt	0	—	0	5	5	1	1	16	10	22
	Net debt	(2)	—	(8)	(21)	(30)	(89)	(53)	(19)	3	5
	Shareholders’ equity	(8)	—	4	18	30	78	42	27	14	6
Returns, %
Returns, %	ROA	(824.30)	—	(112.91)	(111.03)	(67.32)	(61.80)	(66.47)	(95.84)	(107.16)	(101.61)
	ROIC	0.00	—	0.00	0.00	(6,170.28)	0.00	0.00	(491.69)	(163.75)	(165.22)
	ROE	215.32	—	301.12	(185.06)	(94.22)	(79.46)	(92.84)	(174.07)	(224.55)	(323.58)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026 · fundamentals updated 28 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
ADGM Adagio Medical Holdings, Inc.	$2.8M	— (loss-making)	—	−33.50% (below 0%: shrinking)	n/m	−12.86% (below 0%: shrinking)	0.00%	0.00%	Compare
IVF INVO Fertility, Inc	$2.8M	0.0×	— (loss-making)	+16.73% (above 0%: growing)	n/m	+35.07% (above 0%: growing)	35.06%	(59.28%)	Compare
NXL Nexalin Technology, Inc.	$2.6M	— (loss-making)	— (loss-making)	−82.72% (below 0%: shrinking)	n/m	−97.23% (below 0%: shrinking)	72.95%	(18,420.49%)	Compare
BIOLQ Biolase, Inc.	$2.3M	— (loss-making)	— (loss-making)	−0.65% (below 0%: shrinking)	n/m	−60.22% (below 0%: shrinking)	40.39%	(6.41%)	Compare
XAIR Beyond Air, Inc.	$2.2M	— (loss-making)	— (loss-making)	+0.45% (above 0%: growing)	n/m	−9.10% (below 0%: shrinking)	12.73%	(373.98%)
NUVOQ Holdco Nuvo Group D.G Ltd.	$2.1M	— (loss-making)	—	—	n/m	−1.05% (below 0%: shrinking)	0.00%	0.00%	Compare
VJET Flyte Aviation, Inc.	$2.1M	— (loss-making)	— (loss-making)	+380.66% (above 0%: growing)	n/m	−26.70% (below 0%: shrinking)	9.62%	(388.13%)	Compare
NUWE Nuwellis, Inc.	$2.0M	— (loss-making)	— (loss-making)	+14.14% (above 0%: growing)	n/m	−51.55% (below 0%: shrinking)	76.08%	(160.94%)	Compare
AFIB Acutus Medical, Inc.	$1.7M	— (loss-making)	— (loss-making)	+204.18% (above 0%: growing)	n/m	+76.40% (above 0%: growing)	14.20%	(3.81%)	Compare
Median of peers	$2.2M	—	—	+14.14%	—	−19.78%	24.63%	(32.84%)

All 149 Medical Devices stocks →

Beyond Air, Inc. (XAIR) key facts

Strength: Beyond Air, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $7.7 million, up 107.3% from fiscal 2025.
Beyond Air, Inc. (XAIR) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, XAIR traded at $2.16, a market capitalization of $2.2 million.
Return on equity was −323.6% and debt-to-equity 7.89.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −14.40 (distress zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 28, 2026.